Mixed neuroendocrine-non-neuroendocrine neoplasm of the colon treated with laparoscopic resection and adjuvant chemotherapy: a case report
- PMID: 39799545
- DOI: 10.1007/s12328-024-02089-5
Mixed neuroendocrine-non-neuroendocrine neoplasm of the colon treated with laparoscopic resection and adjuvant chemotherapy: a case report
Abstract
Mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) of the colon is rare with a poor prognosis. Since the first description of a mixed neoplasm 100 years ago, the nomenclature has evolved, most recently with the 2022 World Health Organization (WHO) classification system. We describe our experience of a case of locoregionally advanced MiNEN of the descending colon treated with curative laparoscopic resection and adjuvant chemotherapy. The patient is a 72 year old woman who presented with haematochezia. Initial clinical diagnosis was poorly differentiated adenocarcinoma of the descending colon, cT2N0M0, cStage I. Laparoscopic partial colectomy of the descending colon with D3 lymph node dissection and intracorporeal overlap anastomosis was performed. The pathological diagnosis however, returned mixed adenocarcinoma-neuroendocrine carcinoma (MANEC) of the descending colon, pT4aN1bM0, pStage IIIB, a subgroup of MiNEN: 70% was neuroendocrine carcinoma (NEC), whilst poorly differentiated mucinous carcinoma constituted 30% of the tumour. She completed 4 courses of irinotecan plus cisplatin (IP) adjuvant chemotherapy and is currently recurrence-free at postoperative year 2. The clinical course of MiNEN depends on the biology of the two components, both of which must be pathologically characterised. Even quantitatively discrete components should be carefully subtyped as their prognostic relevance is undetermined.
Keywords: Adjuvant chemotherapy; Descending colon; Laparoscopic resection; Mixed adenocarcinoma–neuroendocrine carcinoma (MANEC); Mixed neuroendocrine–non-neuroendocrine neoplasm (MiNEN).
© 2025. Japanese Society of Gastroenterology.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare that they have no conflict of interest. Human and animal rights: This article does not contain any studies with human participants or animals performed by any of the authors. Informed consent: For this type of study, formal consent is not required.
References
-
- Litmeyer AS, Konukiewitz B, Kasajima A, et al. High expression of insulinoma-associated protein 1 (INSM1) distinguishes colorectal mixed and pure neuroendocrine carcinomas from conventional adenocarcinomas with diffuse expression of synaptophysin. J Pathol Clin Res. 2023;9(6):498–509. - DOI - PubMed - PMC
-
- RARECAREnet list excel spreadsheet. RARECARENet—information network on rare cancers. 2015. https://www.rarecarenet.eu/rarecarenet/images/Resources/RARECAREnet_list... . Accessed Oct 1, 2024.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
